Verition Fund Management
SUPN icon

Verition Fund Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Verition Fund Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,501
Closed -$621K – 3466
2025
Q4 		$621K Buy
12,501
+7,862
+169% +$382K ﹤0.01% 2498
2025
Q3 		$222K Sell
4,639
-8,355
-64% -$336K ﹤0.01% 3440
2025
Q2 		$410K Buy
+12,994
New +$416K ﹤0.01% 3046
2024
Q2 		– Sell
-11,494
Closed -$392K – 3253
2024
Q1 		$392K Buy
+11,494
New +$342K ﹤0.01% 2141
2023
Q4 		– Sell
-9,805
Closed -$270K – 2667
2023
Q3 		$270K Buy
+9,805
New +$298K ﹤0.01% 1798
2020
Q1 		– Sell
-43,400
Closed -$1.03M – 1037
2019
Q4 		$1.03M Buy
+43,400
New +$1.05M 0.02% 440
2019
Q3 		– Sell
-35,898
Closed -$1.19M – 1316
2019
Q2 		$1.19M Buy
+35,898
New +$1.23M 0.03% 377
2014
Q4 		– Sell
-13,325
Closed -$116K – 637
2014
Q3 		$116K Buy
+13,325
New +$120K 0.02% 629

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verition Fund Management's SUPN Position: Q1 2026 in Review

Verition Fund Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 12,501 shares — an estimated $621K sold.

Verition Fund Management first reported a position in SUPN in Q3 2014 and held it in 8 quarters. The position peaked at $1.19M in Q2 2019. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Verition Fund Management reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 12,501 Supernus Pharmaceuticals shares in Q1 2026, an estimated $621K.
  • Verition Fund Management first reported a position in Supernus Pharmaceuticals in Q3 2014 and held it in 8 quarters.
  • Verition Fund Management's Supernus Pharmaceuticals position peaked at $1.19M in Q2 2019.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.